Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 20/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 16/20 | 0.67 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.57 |
| ▸ | TP53BP1 | Q12888 | 5/20 | 0.50 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508111 | 0.98 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL4344904 | 0.87 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5741447 | 0.86 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL13664661 | 0.85 | ALDH1A1 (0.47) | L3MBTL3L3MBTL1 | |
| SCHEMBL4342728 | 0.84 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL28462797 | 0.84 | P2RY6 (0.45) | L3MBTL3L3MBTL1 | |
| SCHEMBL23682775 | 0.82 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5483821 | 0.76 | CYP3A4 (0.38) | L3MBTL3L3MBTL1 | |
| SCHEMBL12082201 | 0.76 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL77669 | 0.76 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20050239843-A1 | Diaminothiazoles | DING QINGJIE | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239843-A1 | Diaminothiazoles | CDK4, CDK2, CDK1 | L3MBTL3 3681/4885L3MBTL1 2799/4885MBTD1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.